Bayer’s stock ended last week perched precisely on its 50-day moving average, a technical equilibrium that masks a swirl of corporate and legal events. The German drugmaker closed a $300 million upfront biotech acquisition, received a favorable procedural ruling in the long-running Roundup litigation, and faced the opening salvo of a US trade investigation targeting German drug pricing. The shares gained nearly 5% on the week to close at €37.80 — exactly the 50-day line — as traders weighed a clutch of catalysts that could define the summer.
The closure of the Perfuse Therapeutics deal on 17 June marks a step forward for Bayer’s ophthalmology pipeline. The California-based biotech now sits fully inside the pharmaceutical division, with an upfront payment of $300 million and potential milestone payments that could lift the total consideration to $2.45 billion. The centrepiece asset is PER-001, an intravitreal implant engineered for sustained drug release, currently in Phase II testing for glaucoma and diabetic retinopathy. Bayer sees the compound as a potential first-in-class disease-modifying therapy for two conditions that together affect hundreds of millions of patients worldwide.
On the legal front, a federal judge handed Bayer a clear procedural win in the Roundup saga. Judge Henry E. Autrey of the Eastern District of Missouri ruled that the King v. Monsanto settlement class action belongs in state court, not federal, rejecting arguments from a group of cancer victims who wanted to keep the case in a federal forum. Autrey noted that only Bayer, as the defendant, had the right to move the case to federal court — and it had not done so. The decision sends the matter back to Judge Timothy Boyer in St. Louis, who preliminarily approved the settlement in March. The final fairness hearing is scheduled for 9 July 2026. Plaintiffs opposed to the deal have already appealed Autrey’s order.
The proposed settlement, unveiled in February, is designed to resolve nearly all of the roughly 65,000 outstanding Roundup claims through a new settlement class. Bayer has already spent more than $10 billion resolving prior litigation. The financial drag is far from over: management expects €5 billion in legal cash outflows in 2026 alone, which could push free cash flow as low as negative €2.5 billion.
Should investors sell immediately? Or is it worth buying Bayer?
A separate front opened on Thursday when the Office of the US Trade Representative launched a Section 301 investigation into Germany over its drug-pricing policies. Washington alleges that the German government artificially suppresses prices for innovative medicines, shifting an unfair share of global R&D costs onto US patients. Bayer, as a major exporter of pharmaceuticals, could face tariffs on German-made drugs if the probe leads to trade action. Public comments are due in August, with a hearing set for September. Several large drugmakers, including Pfizer, have already warned that such policies could trigger investment cuts or delayed product launches in Germany.
The equity market sent a subtle signal: Goldman Sachs trimmed its Bayer holding, lowering its aggregate voting rights stake to 4.84% from 5.40%. The bulk remains held through financial instruments, with only 0.20% in direct shares.
All eyes now turn to the US Supreme Court, which is expected to publish a new order list on Monday. Bayer is awaiting a ruling on whether federal pesticide labelling rules preempt state-law failure-to-warn claims — a decision that could reshape the entire Roundup litigation landscape. A verdict is anticipated by the end of July. Between that, the state-court hearing on 9 July 2026, and the intensifying trade scrutiny, Bayer enters a stretch where each headline could tip the stock one way or the other. For now, the shares sit dead on their 50-day average, and the next move depends on which of these threads pulls hardest.
Ad
Bayer Stock: Buy or Sell?! New Bayer Analysis from June 20 delivers the answer:
The latest Bayer figures speak for themselves: Urgent action needed for Bayer investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from June 20.
Bayer: Buy or sell? Read more here...
